Teva Pharmaceutical Industries Stock Cash And Equivalents
| TEVJF Stock | USD 17.80 0.00 0.00% |
Teva Pharmaceutical Industries fundamentals help investors to digest information that contributes to Teva Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Teva Pink Sheet. The fundamental analysis module provides a way to measure Teva Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Teva Pharmaceutical pink sheet.
Teva |
Teva Pharmaceutical Industries Company Cash And Equivalents Analysis
Teva Pharmaceutical's Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Teva Pharmaceutical Cash And Equivalents | 2.06 B |
Most of Teva Pharmaceutical's fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Teva Pharmaceutical Industries is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
| Competition |
In accordance with the recently published financial statements, Teva Pharmaceutical Industries has 2.06 B in Cash And Equivalents. This is 150.95% higher than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The cash and equivalents for all United States stocks is 23.76% higher than that of the company.
Teva Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Teva Pharmaceutical's direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Teva Pharmaceutical could also be used in its relative valuation, which is a method of valuing Teva Pharmaceutical by comparing valuation metrics of similar companies.Teva Pharmaceutical is currently under evaluation in cash and equivalents category among its peers.
Teva Fundamentals
| Return On Equity | -0.24 | |||
| Return On Asset | 0.0363 | |||
| Profit Margin | (0.16) % | |||
| Operating Margin | 0.18 % | |||
| Current Valuation | 28.75 B | |||
| Shares Outstanding | 1.11 B | |||
| Shares Owned By Insiders | 0.77 % | |||
| Shares Owned By Institutions | 5.30 % | |||
| Price To Earning | 14.56 X | |||
| Price To Book | 1.10 X | |||
| Price To Sales | 0.69 X | |||
| Revenue | 14.93 B | |||
| Gross Profit | 6.97 B | |||
| EBITDA | (1.68 B) | |||
| Net Income | (2.41 B) | |||
| Cash And Equivalents | 2.06 B | |||
| Cash Per Share | 1.85 X | |||
| Total Debt | 19.1 B | |||
| Debt To Equity | 2.28 % | |||
| Current Ratio | 1.11 X | |||
| Book Value Per Share | 7.11 X | |||
| Cash Flow From Operations | 1.59 B | |||
| Earnings Per Share | (0.56) X | |||
| Price To Earnings To Growth | 0.80 X | |||
| Number Of Employees | 34 K | |||
| Beta | 1.22 | |||
| Market Capitalization | 10.99 B | |||
| Total Asset | 44.01 B | |||
| Retained Earnings | 14.99 B | |||
| Working Capital | (1.9 B) | |||
| Current Asset | 17.39 B | |||
| Current Liabilities | 19.29 B | |||
| Net Asset | 44.01 B |
About Teva Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Teva Pharmaceutical Industries's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Teva Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Teva Pharmaceutical Industries based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Teva Pink Sheet
Teva Pharmaceutical financial ratios help investors to determine whether Teva Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Teva with respect to the benefits of owning Teva Pharmaceutical security.